Hover a dot or row, or tab through the dots · bars scaled to the largest round ($215M)
Form D offerings
One line per offering, amendments folded in, newest first
Form D offerings
File
First filed
Latest
Sought
Sold
Investors
Exemptions
021-420716
First filed2021-11-10
Latest2021-11-10
Sought$215M
Sold$215M
Investors37
Exemptions506(b)
021-287829
First filed2017-06-01
Latest2017-08-02
Sought$15.6M
Sold$15.6M
Investors10
Exemptions506(b)
Who backs Arbor Biotechnologies, Inc. — 1 inferred investor — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2021-11-10
Related persons
Name
Relationship
MARK ANGELINO
RelationshipDirector
KEITH CRANDELL
RelationshipDirector
RAMI HARAWI
RelationshipDirector
PAUL MEISTER
RelationshipDirector
DAVID WALT
RelationshipDirector
DEVYN SMITH
RelationshipExecutive Officer, Director
DAVID CHENG
RelationshipExecutive Officer
PAM STETKIEWICZ
RelationshipExecutive Officer
JOHN MURPHY
RelationshipExecutive Officer
KELLY MORGAN
RelationshipExecutive Officer
CHEN YU
RelationshipDirector
Facts
As its latest Form D states them
Industry
Biotechnology
State
Massachusetts (MA)
Exemptions
Rule 506(b)
First filed
2017-06-01
Latest filing
2021-11-10
Who backs Arbor Biotechnologies, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
Inferred investors — the funds and firms behind it, from co-filings and shared people
Every Form D and amendment as filed, with what each one stated
Its rounds in sequence: the gap between them and whether they grew
Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)